Tumor-associated antigen recognized by the 22-1-1 monoclonal antibody encourages colorectal cancer progression under the scanty CD8+ T cells

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 411-416

  Oshikiri, Taro ^a,c   Miyamoto, Masaki ^b   Morita, Takayuki ^a   Fujita, Miyoshi ^a   Miyasaka, Yuji ^a   Senmaru, Naoto ^a   Yamada, Hidehisa ^a   Takahashi, Toshiyuki ^a   Horita, Shoichi ^a   Kondo, Satoshi ^b  

^a Hokkaido Gastroenterology Hospital   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Hokkaido Gastroenterology Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 22 1 1; N ACETYLGALACTOSAMINE; RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UNIVARIATE ANALYSIS;

ACETYLGALACTOSAMINE; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 31544478573     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1257     Document Type: Article

References (25)

1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
3. Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw Hill; 1998. p. 565-87.
4. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-6.
5. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 1990;3:332-5.
6. Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum Pathol 1995;26:31-8.
7. Pihl E, Nairn RC, Milne BJ, Cuthbertson AM, Hughes ES, Rollo A. Lymphoid hyperplasia: a major prognostic feature in 519 cases of colorectal carcinoma. Am J Pathol 1980;100:469-80.
8. Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77:1501-9.
9. Hiraoka K, Hida Y, Miyamoto M, et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002;99:418-23.
10. Oshikiri T, Hida Y, Miyamoto M, et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 2001;85:1922-7.
11. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens [review]. Annu Rev Med 1996;47:481-91.
12. + T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 2003;84:224-8.
13. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
14. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318-24.
15. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42.
16. Fukuda M, Tanaka A, Hamao A, Suzuki S, Kusama K, Sakashita H. Expression of RCAS1 and its function in human squamous cell carcinoma of the oral cavity. Oncol Rep 2004;12:259-67.
17. Nakamura Y, Yamazaki K, Oizumi S, et al. Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci 2004;95:260-5.
18. Engelsberg A, Hermosilla R, Karsten U, Schulein R, Dorken B, Rehm A. The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glycan antigens. J Biol Chem 2003;278:22998-3007.
19. + lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur J Surg Oncol 2004;30:53-7.
20. Leelawat K, Watanabe T, Nakajima M, Tujinda S, Suthipintawong C, Leardkamolkarn V. Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J Clin Pathol 2003;56:764-8.
21. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
22. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991;12:415-9.
23. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003;63:1555-9.
24. Okada K, Nakashima M, Komuta K, et al. Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Mod Pathol 2003;16:679-85.
25. Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF, Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995;76:1700-8.